Royal Bank of Canada
EW icon

Royal Bank of Canada’s Edwards Lifesciences EW Stock Holding History

Royal Bank of Canada’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-300,000
Closed -$3.29M – 5961
2013
Q4 		$3.29M Hold
300,000
– – ﹤0.01% 1942
2013
Q3 		$3.48M Hold
300,000
– – ﹤0.01% 1810
2013
Q2 		$3.36M Buy
+300,000
New +$3.55M ﹤0.01% 1721

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Royal Bank of Canada's EW Position: Q1 2026 in Review

Royal Bank of Canada increased its Edwards Lifesciences (EW) stake by 18% in Q1 2026, buying an estimated $31M and bringing the position to 2,446,999 shares worth $196M. The position accounts for 0.03% of the portfolio, ranked #413.

Royal Bank of Canada first reported a position in EW in Q2 2013 and has held it in 52 quarters since. The position peaked at $842M in Q4 2021. 1,287 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • Royal Bank of Canada held 2,446,999 shares of Edwards Lifesciences worth $196M as of Q1 2026.
  • Royal Bank of Canada bought 375,801 Edwards Lifesciences shares in Q1 2026, an estimated $31M.
  • Edwards Lifesciences made up 0.03% of Royal Bank of Canada's portfolio in Q1 2026, its #413 holding.
  • Royal Bank of Canada first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 52 quarters since.
  • Royal Bank of Canada's Edwards Lifesciences position peaked at $842M in Q4 2021.
  • 1,287 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.